Vanda Pharmaceuticals $VNDA
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-310
RECRUITING9
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO33%
Delay Index: of 9 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Vanda Pharmaceuticals on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tradipitant NCT04326426 |
P3 | Enrolling by invitation | Coronavirus Infection | 300 | 2020-08-01 |
| Tasimelteon NCT06701396 |
P3 | Recruiting | Sleep Wake Disorders; Sleep Disorders, Circadian Rhythm | 60 | 2025-06-30 |
| Trichostatin A NCT07065773 |
P2 | Active, not recruiting | Onychomycosis of Toenail | 50 | 2026-09 (+6 mo) |
| VSJ-110 NCT07179055 |
P2 | Recruiting | Dry Eye | 160 | 2026-09 |
| iloperidone NCT07090161 |
P2 | Recruiting | Hypertension; Uncontrolled Hypertension | 240 | 2026-10 |
| VQW-765 NCT07221578 |
P3 | Active, not recruiting | Social Anxiety Disorder (SAD) | 500 | 2026-12 |
| Tradipitant NCT07446439 |
P3 | Recruiting | Nausea and Vomiting; Obesity | 280 | 2026-12-01 |
| VCA-894A NCT07223632 |
P1/2 | Active, not recruiting | Charcot Marie Tooth Disease (CMT); Neuromuscular Diseases (NMD) | 1 | 2027-03 (+12 mo) |
| Tradipitant NCT06138613 |
P3 | Active, not recruiting | Motion Sickness | 705 | 2027-09-30 (+38 mo) |
| iloperidone NCT06961968 |
P3 | Recruiting | Schizophrenia | 400 | 2027-11 |
| Tasimelteon Oral Suspension NCT06953869 |
P3 | Recruiting | Insomnia Disorder | 420 | 2027-11 |
| Milsaperidone NCT06830044 |
P3 | Recruiting | Major Depressive Disorder (MDD) | 500 | 2028-03 |
| Ponesimod NCT07362017 |
P3 | Recruiting | Moderate-to-severe Chronic Plaque Psoriasis | 300 | 2028-08 |
| Ponesimod NCT07686081 |
P3 | Recruiting | Ulcerative Colitis (UC) | 150 | 2029-04 |